Business Context and Reporting Period
This Form 6-K, dated June 29, 2018, reports on Novartis AG's strategic decision to spin off its Alcon eye care devices business into a standalone, publicly traded company. The filing also announces a new share buyback program. The transaction is subject to shareholder approval at the 2019 Annual General Meeting (AGM) and is expected to be completed in the first half of 2019.
Key Financial Metrics
- Share Buyback: Novartis plans to initiate a share repurchase program of up to USD 5 billion, to be executed by the end of 2019.
- Funding Source: The buyback is planned to be largely funded by proceeds from the divestment of the consumer health joint venture stake to GSK, net of AveXis acquisition payments.
- Alcon Financials (2017): The Alcon division generated approximately USD 7 billion in sales in 2017.
- Novartis Group Financials (2017): Net sales were USD 49.1 billion, with R&D spending of approximately USD 9.0 billion.
- Ophthalmology Pharmaceuticals: The portfolio remaining with Novartis generated USD 4.6 billion in sales in 2017.
- Dividend: Novartis intends to continue paying a strong dividend in Swiss francs, building on the CHF 2.80 per share paid in March 2018.
Material Changes and Strategic Actions
- Alcon Spinoff: Novartis will seek shareholder approval to spin off 100% of Alcon. The ophthalmology pharmaceuticals portfolio will remain with Novartis, while Alcon will focus on surgical and vision care devices.
- Leadership Changes: Effective July 1, 2018, Mike Ball will become Chairman-designate of Alcon, and David Endicott will be promoted to CEO of Alcon. Both will report to Novartis CEO Vas Narasimhan until the spinoff is completed.
- Corporate Structure: Alcon will be incorporated in Switzerland with listings planned on the SIX Swiss Exchange and the New York Stock Exchange. Fort Worth will remain a key location.
- Transaction Status: The spinoff is expected to be tax-neutral to Novartis, subject to market conditions, tax rulings, and regulatory approvals.
Guidance, Outlook, and Risks
Management views the spinoff as the best option for shareholders, allowing Novartis to focus as a medicines company and Alcon to pursue its own growth strategy as a global medtech leader. The share buyback reflects confidence in future top-line growth and margin expansion.
Risks and Contingencies:
- Completion of the spinoff and buyback is not guaranteed and depends on shareholder approval, regulatory clearances, and market conditions.
- Forward-looking statements regarding the transaction's benefits, timing, and financial impact are subject to significant risks, including healthcare cost containment, regulatory delays, and patent expirations.
- There is no guarantee that the strategic benefits or synergies will be realized or that the separation will be executed smoothly.
Investor Verification Checklist
- Confirm the final approval of the Alcon spinoff at the February 2019 AGM.
- Verify the execution timeline and actual volume of the USD 5 billion share buyback program.
- Monitor the separation process for any operational disruptions or key personnel departures.
- Track the development and regulatory approval status of RTH258 (brolucizumab) within Novartis's retained ophthalmology portfolio.
- Review the final tax rulings to confirm the transaction remains tax-neutral for Novartis.